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People with diabetes experience chronic hyperglycemia and are at a high risk of developing 
atherosclerosis and microvascular disease.  Reactions of glucose, or aldehydes derived from 
glucose (e.g. methylglyoxal, glyoxal, or glycolaldehyde), with proteins results in glycation that 
ultimately yield advanced glycation end products (AGE).  AGE are present at elevated levels in 
plasma and atherosclerotic lesions from people with diabetes, and previous in vitro studies have 
postulated that the presence of these materials be deleterious to cell function.  This accumulation 
of AGE and glycated proteins within cells may arise from either increased formation and / or 
ineffective removal by cellular proteolytic systems, such as the proteasomes, the major multi-
enzyme complex that removes proteins within cells. In this study it is shown that whilst high 
glucose concentrations fail to modify proteasome enzyme activities in J774.A1 macrophage-like 
cell extracts, reactive aldehydes enhanced proteasomal enzyme activities.  In contrast BSA, pre-
treated with high glucose for 8 weeks, inhibited both the chymotrypsin-like and caspase-like 
activities. BSA glycated using methylglyoxal or glycolaldehyde, also inhibited proteasomal 
activity though to differing extents. This suppression of proteasome activity by glycated proteins 
may result in further intracellular accumulation of glycated proteins with subsequent deleterious 
effects on cellular function. 
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The continuous synthesis and degradation of proteins plays an essential role in the 
maintenance of cellular homeostasis and regulation of multiple cellular functions [1,2].  This 
continuous protein turnover minimises protein exposure to oxidants or other damaging agents, 
and therefore reduces the potential accumulation of materials with modified structure or function 
[1].  However, despite this continuous turnover of proteins in most cells and tissues, evidence has 
been presented for an accumulation of modified proteins in a wide range of age-related diseases 
including Alzheimer’s disease, Parkinson’s disease, cataractogenesis, atherosclerosis and diabetes 
[3,4].  This accumulation implies either an increased rate of formation of damaged proteins or a 
decreased rate of removal, or both. 
People with diabetes have elevated levels of modified proteins arising from glycation and 
glycoxidation reactions [5]. Glycated proteins arise from the nonenzymatic reaction of glucose, 
and reactive aldehydes derived from glucose with proteins, lipids and nucleic acids ultimately 
yields advanced glycation end products (AGE) [6,7]. In a normal healthy population the level of 
glycated products on plasma proteins (e.g. albumin) are <3 %, whilst in people with diabetes this 
proportion can be increased very dramatically [8,9]. Elevated levels of a number of low 
molecular mass aldehydes, including glyoxal (GO), methylglyoxal (MGO), 3-deoxyglucosone 
and glycolaldehyde (GA) have also been detected in people with diabetes [6].  GA can be 
generated from glucose and amino acid oxidation [10], GO from glucose oxidation [11] and 
MGO from the degradation of glucose, glycerone phosphate, glyceraldehyde 3-phosphate, 
acetone, aminoacetone and amino acid oxidation [12-14].  Glycation reactions occur more rapidly 
with reactive aldehydes, such as GA, GO and MGO, than with glucose [6,15].  The elevated 
levels of these reactive aldehydes can be due to an increase in the rate of generation of these 
aldehydes [13] and/or deficiencies in their removal systems [13,16,17].  Previous studies have 
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reported an upregulation of systems that detoxify these reactive aldehydes, including glyoxalases 
(glyoxalase I and II) [13,16,17] and aldose reductase [16].  However, these systems do not appear 
able to compensate adequately for an increased formation of reactive aldehydes in people with 
diabetes, and particularly those with complications [13,16,17].   
When damage to proteins is unable to be repaired by primary cellular defences, such as 
protein disulfide isomerases (which reduce disulfide bonds), methioine sulfoxide reductases 
(which reduce the sulfoxide back to the thio ether) or molecular chaperones (which refold 
partially denatured proteins), the altered proteins are targeted for degradation by cellular protein 
removal systems [1].  The two major systems in eukaryotic cells responsible for this action are 
the endo-lysosomal system and proteasomes [3].  The latter, which are the major proteolytic 
pathway for intracellular proteins, are members of a class of proteases known as the N-terminal 
nucleophile hydrolases [18,19].  The 26S proteasomal complex appears to account for majority of 
the ATP- and ubiquitin-stimulated proteolytic activity, and consists of a 20S proteolytic core and 
one or two 19S regulatory units [18,20,21].  There are three different types of active sites; two 
chymotrypsin-like (β5 subunit), two trypsin-like (β2 subunit) and two caspase-like (or PGPH) (β1 
subunit).  The activities of each of these three sites need to be evaluated in order to obtain a 
complete picture of the state of the proteasomal system inside cells, or the potency of inhibitors 
[21].  Previous studies have reported an age-related decline in the peptidase activities of the 20S 
and 26S proteasome in humans, with this decrease postulated to give rise to an accumulation of 
damaged proteins [22]. 
Reactive aldehydes (MGO, GO and GA) and pre-glycated proteins have been reported to 
alter cellular function via suppression of the activity of key cellular enzymes including 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, a key glycolytic enzyme), glutathione 
 5 
reductase (GR, an important antioxidant enzyme), and lactate dehydrogenase (LDH) [23]. These 
aldehydes have also been demonstrated to inhibit cysteine proteases (cathepsins B, L and S) of 
the lysosomal cathepsin family in macrophage cell lysates in a concentration-dependent manner 
[7]. Under the same concentrations glucose or proteins pre-glycated with glucose had no effect 
[7,23].  This inhibition has been suggested to arise from aldehyde-induced modification of the 
thiol groups of these enzymes [7,23].  It has also been suggested that elevated levels of free low 
molecular mass aldehydes (GA, GO and MGO) play an essential role in diabetes-associated 
atherosclerosis via the formation of glycated low-density lipoprotein particles which may 
contribute to lipid-loading of macrophage cells in the artery wall [24].  The aim of the current 
study was therefore to test the hypothesis that elevated levels of glucose and reactive aldehydes, 
and pre-glycated proteins (generated by glucose and reactive aldehydes) may modulate the 
activity of the proteasome system, as this system appears to play an essential role in degradation 
of these modified proteins [1]. 
 
Materials and methods 
Materials 
Proteasomal enzyme activity was quantified using the pro-fluorescent peptides N-Suc-
Leu-Leu-Val-Tyr-AMC (chymotrypsin-like activity), and Boc-Leu-Ser-Thr-Arg-AMC (trypsin-
like activity) purchased from Sigma-Aldrich (Castle Hill, NSW, Australia).  Caspase-like activity 
was examined using Ac-Nle-Pro-Nle-Asp-AMC (Auspep, Parkville, VIC, Australia).  All 
substrates were prepared as 100 x stocks in DMSO (10 mM for chymotrypsin and caspase 
substrates, 60 mM for trypsin) [21] and stored at – 20 ºC.  Glucose and sodium dihydrogen 
orthophosphate monohydrate (Na2HPO4.H2O) were obtained from Merck (Kilsyth, VIC, 
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Australia), digitonin from Calbiochem (La Jolla, CA, USA), disodium hydrogen orthophosphate 
dodecahydrate (Na2HPO4.12 H2O) from Univar (Seven Hills, NSW, Australia), dithiothreitol was 
from Astral Scientific (Gymea, NSW, Australia), and Tris hydrochloride from Amresco (Solon, 
OH, USA).  All other chemicals were obtained from Sigma-Aldrich (Castle Hill, NSW, 
Australia) unless otherwise noted.  All solutions were prepared using nanopure water (Milli Q 
system, Millipore-Waters, Lane Cove, NSW, Australia) and treated with washed Chelex-100 
resin (Bio-Rad, Regents Park, NSW, Australia) to remove trace metal ions. 
 
Preparation of glycated BSA  
Extensively glycated BSA was prepared by incubation of BSA (50 mg mL-1) with D-
glucose (1 M) in 200 mM phosphate buffer (0.2 M Na2HPO4.12H2O and NaH2PO4.H2O, pH 7.4, 
pre-treated with Chelex 100 resin to remove trace metal ions) at 37 ºC for 8 weeks under sterile 
conditions and an atmosphere of humidified 5% CO2.  Control BSA samples were incubated in a 
similar manner in the absence of glucose [7].  BSA modified by methylglyoxal (MGO), 
glycolaldehyde (GA) or glucose was generated by incubating BSA (80 mg mL-1) with MGO or 
glucose at 10 and 200 mM, or GA at 10 mM, for 17 h at 37 ºC in 50 mM phosphate buffer (pH 
7.4).  Control BSA was incubated in a similar manner in the absence of MGO, GA or glucose.  
Immediately after incubation, protein samples were passed through 2 successive PD10 columns 
(Amersham Bioscience, Castle Hill, NSW, Australia) using chelexed-treated 50 mM phosphate 
buffer, pH 7.4, as the eluting buffer to remove unbound MGO, GA or glucose.  With the 
exception of BSA incubated with glucose for 17 h where little adduction occurs, these 
incubations result in the formation of BSA with multiple covalently-bound sugar molecules or 
aldehyde groups [25-27] (see also below). Protein concentrations were determined using the 
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Pierce (Rockford, IL, USA) bicinchoninic acid (BCA) assay with commercial BSA used as a 
standard [28].   
 
Characterization of glycated BSA 
The nature and extent of BSA glycation was assessed for each condition by HCl 
hydrolysis of triplicate samples as described previously [29], with modifications according to 
Zeng and Davies [30]. Briefly, vials containing 0.4 mg of protein were placed in Pico-Tag 
reaction vials (Alltech, Baulkham Hills, NSW, Australia) containing 1 mL of 6 M HCl and 50 µL 
of thioglycolic acid. The reaction vials were subsequently evacuated and flushed with nitrogen 
gas three times, before hydrolysis under vacuum for 17 hours at 110 oC. Following drying down 
using a vacuum concentrator (Christ RVC 2-33; John Morris Scientific, Chatswood, NSW, 
Australia), samples were resuspended in 400 µL of 0.2 M borate buffer, pH 9.0, and filtered 
through 0.2 µm centrifugal filter units (Pall Nanosep MF; 500 µL capacity). Samples were kept at 
4 oC prior to HPLC analysis. 
Separation and quantification of AGEs was carried out by gradient HPLC using a 
Shimadzu HPLC system (Shimadzu Oceania, Rydalmere, NSW, Australia) consisting of a SIL-
10ADVP auto injector (capable of pre-column derivatization), two LC-10ATVP pumps, DGU-
20A3 degasser, SCL-10-10AVP system controller, CTO-10ASVP column oven (set at 30 oC) and 
RF-10AXL fluorescence detector. The column used was a Beckman Coulter Ultrasphere ODS 
column (250 x 4.6 mm, 5µm pore size) with corresponding guard column (45 x 4.6 mm). Buffer 
A was composed of 4.8% (v/v) 1 M sodium acetate pH 6.5 in water, 4% (v/v) methanol, and 
water, whilst buffer B consisted of 100% methanol. A solvent gradient was utilized at 1 mL/min, 
which consisted of 15% buffer B for 40 min, 15-37% B over 36 min, 37-90% B over 2 min, 90% 
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B for 7 min, 90-5% B over 1 min, and re-equilibration at 15% B for 9 min (total run time 95 
min).  
AGEs were quantified using authentic standards, which were used to construct standard 
curves over the range of 0-100 pmoles per injection:  Nε-carboxymethyllysine (CML; Sigma); Nε-
carboxyethyllysine (CEL; Toronto Research Chemicals); (2S)-2-amino-5-(5-methyl-4-oxo-4,5-
dihydro-1H-imidazol-2-ylamino)-pentanoic acid (MG-H1; PolyPeptide Laboratories); (2S)-2-
amino-5-(2-amino-5-methyl-4-oxo-4,5-dihydro-imidazol-1-yl)-pentanoic acid (MG-H2; two 
isomers can be detected for this product, designated 2a and 2b; PolyPeptide Laboratories). One 
minute prior to injection, 40 µL of each sample/standard was derivatized by the addition and 
mixing of 20 µL of o-phthaldialdehyde (OPA) containing 0.5% (v/v) 2-mercaptoethanol. Forty 
µL of each sample was injected, and 30 µL of each standard. The fluorescent derivatives were 
detected by fluorescence using λex 340 nm and λem 440 nm. Samples were diluted as required to 
ensure that all analytes were within the range of the relevant standard curves. Limits of detection 
for the AGEs were approx. 0.2 nmoles AGE per mg of protein. All samples were standardized to 
their Gly content, as quantified by HPLC, thus serving as their own internal standards. Samples 
were diluted 100-fold with water, and separated using the same HPLC system and pre-column 
derivatization as for AGE detection, but with different buffers and gradient. Buffer A consisted of 
20% (v/v) methanol, 5% (v/v) tetrahydrofuran, 10% aqueous 1 M sodium acetate pH 5.0, and 
water; buffer B was identical except it contained 80% (v/v) methanol in place of the 20% (v/v) 
methanol in buffer A. The following gradient was used: 5% B for 7 min, 5-25% B over 10 min, 
25-50% B over 10 min, 50% B for 8 min, 50-100% B over 5 min, 100% B for 5 min, 100-5% B 
over 1 min, and re-equilibration at 5% B for 9 min (total run time 54 min). Fifteen µL of each 
derivatized sample/standard was injected. The standards used were commercial products (Sigma), 
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with standard curves prepared over the range 0-50 pmoles per injection; this also allowed 
quantification of Arg in each sample. 
 
Cell culture 
J774A.1 mouse macrophage-like cells (TIB-67, ATCC, Manassas, VA, USA) were grown 
in 175 cm2 Falcon flasks (Becton Dickinson, Franklin Lakes, NJ, USA) in Dulbecco’s modified 
Eagle’s medium (DMEM) with added heat-inactivated foetal calf serum (FCS) (10% (v/v); JRH 
Biosciences, Lenexa, Kansas, USA), 2 mM L-glutamine (Thermo Electron, Melbourne, VIC, 
Australia) and penicillin/streptomycin (100 units mL-1 and 0.1 mg mL-1, respectively; 
BioWhittaker (Lonza, Walkersville, MD, USA)).  Cells were harvested by scraping using a 
disposable cell scraper (Greiner Bio-One, Frickenhausen, Germany) and the cell suspension 
replated at 1:16 dilution every 3-4 days.  Cell extracts for proteasome measurement activity, were 
prepared from confluent cultures of J774A.1 cells contained in 75 cm2 Falcon flasks.  The media 
was replaced with cold PBS, the cells removed by scraping, and subsequently washed three times 
in cold PBS by centrifugation (Beckman, Palo Alto, CA, USA) at 524 g for 5 min at 4 ºC.  Cell 
pellets were snap frozen in liquid nitrogen and stored at – 80 ºC. 
 
Preparation of cell extracts for proteasome activity measurement 
Cell extracts containing proteasomes were prepared as described previously [21].  Briefly, 
cell pellets were resuspended in 500 µL of homogenisation buffer (50 mM Tris-HCl, pH 7.5, 250 
mM sucrose, 5 mM MgCl2, 2 mM ATP, 1 mM DTT and 0.5 mM EDTA) containing 0.025% 
(w/v) digitonin.  ATP was employed to prevent dissociation of the 26S proteasome into its 
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components and to ensure that 26S, and not 20S activity, was measured [21].  Resuspended cells 
were incubated on ice for 5 min to allow permeabilisation by digitonin, and were then transferred 
to glass tubes (8 x 34 mm; Beckman, Palo Alto, CA, USA).  The cytosol was forced out by 
centrifugation at 20,000 g for 15 min at 4 ºC using a Beckman centrifuge (120/1, Palo Alto, CA, 
USA).  The optimal protein concentration for the proteasome activity assay was determined to be 
11-12 µg protein/reaction, with dilutions made using homogenisation buffer. 
 
Treatment of cell extracts with free aldehydes, glucose and glycated BSA 
The effect of aldehydes and glucose on proteasome activity, was examined using cell 
extracts incubated with MGO (0.25, 0.5, 1, 10 and 20 mM), GO or GA (1, 10 and 20 mM) at 21 
ºC for 5 min.  Free glucose (5 and 20 mM) was investigated in a similar manner.  The effects of 
glycated BSA on proteasome activity were examined using 0.4, 1 or 4 mg mL-1 pre-glycated BSA 
prepared as described above.  
 
Proteolytic activity measurement and analysis 
Immediately after completion of the incubations with the required materials (free 
aldehyde, glycated BSA, epoxomicin, or no additives), proteolysis was measured by a continuous 
assay of peptidase activity using fluorescence detection [21].  Samples were prepared in reaction 
buffer (50 mM Tris-HCl, pH 7.5, 40 mM KCl, 5 mM MgCl2, 0.5 mM ATP, 1 mM DTT, 0.5 
mg/ml BSA) with 100 µM for the chymotryptic and caspase substrates, or 600 µM tryptic 
substrate.  Fluorescence (λex 360 nm, λem 460 nm) was measured using a Cytofluor II plate reader 
every minute for 30 min.  Potential contributions from non-proteasomal enzyme activity were 
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examined using the proteasome-specific inhibitor epoxomicin with proteosome activity 
considered to be the fraction of fluorescence increase that was sensitive to this agent; fluorescent 
change due to proteasomal activity were therefore calculated as the difference in the rate of 
fluorescence change over time (ΔFU/min) between determinations made in the presence (pre-
incubation with 20 µM reagent at 21 ºC for 30 min) and absence of this agent [21].  
 
Statistical analyses 
Data from all enzymatic activity measurements are expressed as mean ± SEM from 3 or more 
separate experiments, each assayed in triplicate. HPLC samples were analysed from triplicate 
experiments. Statistics analysis was performed using Prism 4.03 (GraphPad software, San Diego, 
CA, USA).  For pair comparisons, paired t tests were employed.  For multiple comparisons, one-
way analysis of variance (ANOVA) with Newman-Keuls Multiple Comparison test was 
employed.  For the AGE and amino acid analyses one-tailed unpaired t-tests were employed with 
the glycated BSA samples to the corresponding control. Results were considered statistically 




Effect of glucose on proteasomal enzyme activities in J774A.1 cell extracts 
Incubation of cell extracts with 5 or 20 mM glucose at 21 ºC for 5 min had no effect on 
chymotrypsin- and trypsin-like activities as compared with glucose-free controls, although a 
dose-dependent trend towards an enhancement in activity was observed (Fig. 1).  With 20 mM 
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glucose a significant increase (ca. 1.5-fold) in caspase-like activity was observed compared to the 
no glucose condition, but this was not significant when compared to the 5 mM glucose system.   
 
Effect of reactive aldehydes on proteasomal enzyme activities in J774A.1 cell extracts 
The effect of reactive aldehydes on the proteasomal enzyme activities were investigated 
by incubation of cell extracts of J774A.1 cells with GA, GO or MGO over the concentration 
range 0.25 - 20 mM, at 21 ºC for 5 min. Proteasomal activities were then quantified as described 
above. Treatment of the proteasomal preparations with all three reactive aldehydes resulted in a 
dose-dependent increase in chymotrypsin-like activity (Fig. 2A).  This increase was statistically-
significant at 10 mM for each aldehyde.  However, at the highest concentration examined there 
was attenuation in activity found with GA treatment, whereas no further increase was observed 
with GO, and the activity was further enhanced with MGO.  Thus the chymotrypsin-like activity 
of the cell extracts of J744A.1 cells differentially responsive to MGO, GO and GA. 
Differences in the response to aldehyde treatment were also observed with the caspase-
like activity (Fig. 2B).  This activity was relatively insensitive to MGO treatment with the 
exception of the highest concentration examined.  In the cases of GA- and GO treatment, a dose-
dependent enhancement in caspase-like activity was apparent with a significant increase detected 
at 10 mM.  Interestingly, a trend towards a suppression of caspase-like activity was observed at 
very high aldehyde levels (20 mM GO, 10 mM MGO) when compared to control, but this did not 
reach statistical-significance. 
Trypsin-like activity was significantly modulated by MGO at 0.5 mM and above, 
resulting in a significant enhancement of activity, with this stimulation being concentration 
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dependent (Fig. 2C).  In contrast, GO and GA only increased trypsin-like activity at high 
concentrations (10 and 20 mM for GA and GO, respectively).  
 
Characterization of BSA modification by glucose and reactive aldehydes 
Modification of the glycated and control BSA was characterized by HPLC analysis. 
Incubation of BSA with 200 mM MGX resulted in the detection of significant levels of the AGEs 
CML, CEL, MG-H1, MGH-2a and MG-H2b (Fig. 3) and 58% loss of parent Arg (Fig. 3). Lys 
residues were also depleted but this was not quantified (see below). Significant Arg modification 
was also evident upon incubation with 10 mM MGX, as evidenced by elevated levels of CML, 
MG-H1, MG-H2a and MG-H2b, and loss of 23% of the parent Arg (Fig. 3). Reaction at Lys 
residues was less marked in this case as judged by the extent of CEL formation (Fig. 3). With GA 
as the modifying agents, elevated levels of CML were detected together with a small, but 
significant, loss of Arg (Fig. 3). 
Incubation of BSA with glucose for 8 weeks resulted in the formation of very high levels 
of CML (over 30-fold greater than 10 mM GA, and over 300-fold greater than MGX), as well as 
significant amounts of CEL. A significant (22%) loss of Arg was also detected, which is not 
accounted for by the concentration of AGEs detected by HPLC, consistent with the formation of 
additional products such as Nω-carboxymethylarginine (CMA), which is known to be formed 
upon incubation of protein with glucose for prolonged periods, but which is susceptible to acid 
hydrolysis [31]. Parent Lys was also depleted in these samples consistent with the formation of 
Lys-derived AGEs (CML, CEL), but this was not quantified absolutely, due to variability in Lys 
derivatization by OPA. No significant AGE formation, or parent Arg, was observed upon 
incubation of BSA with 10 mM or 200 mM glucose for 17 h (Fig. 3). 
 14 
 
Effects of native and glycated proteins on proteasomal enzyme activity  
 The effects of the glycated and control BSA on proteasome activity were examined by 
incubating J774A.1 cell extracts with three different concentrations of native or modified protein 
(0.4, 1 and 4 mg protein mL-1) for 5 min at 21 ºC.  Initial studies examined control (native) 
incubated BSA (Fig. 4).  Chymotrypsin activity was sensitive to inhibition by the highest 
concentration of BSA incubated overnight, or for up to 8 weeks at 37 oC (Fig. 4A).  Caspase-like 
activity was decreased significantly on incubation with the highest concentration of native BSA 
incubated for 8 weeks, but not at shorter times or with lower concentrations (Fig. 4B).  Trypsin-
like activity was unaffected (Fig. 4C).  In the light of this data, subsequent comparisons were 
made versus the corresponding samples incubated with native BSA for the same period. 
BSA pre-glycated with glucose for 17 hr had no significant effects on proteasomal 
activity compared to the incubated protein control (data not shown).  In contrast, BSA glycated 
by incubation with 1 M glucose for 8 weeks, gave rise to a significant inhibition of both the 
chymotrypsin- and caspase-like activities at the highest concentration of BSA used compared to 
the incubated protein control.  The trypsin-like activity was not affected (Fig. 5).  With the 
highest protein concentration (4 mg/ml) an apparent negative gradient was observed; this arises 
from the subtraction of the fluorescence changes observed with the epoxomicin controls from the 
glycated protein data, and is believed to reflect inhibitory effects of the native or glycated BSA 
on other proteolytic systems present in the cell extracts (e.g. calpains and lysosomal cathepsins) 
[21].  
No significant inhibitory effects on the trypsin-like activity of the proteasomal extracts 
was observed with BSA pre-glycated with glucose over the range of BSA and glucose 
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concentrations, and glycation conditions, examined (Fig. 5).  In contrast to the other activities 
(see above) a significant increase in trypsin-like activity was observed with the highest 
concentration of BSA modified with either 10 mM or 200 mM glucose for 17 h (Fig. 5F).   
The effects of BSA glycated by reactive aldehydes on proteasomal enzyme activities were 
examined in a similar manner to that outlined above, with the BSA (0.4, 1 or 4 mg protein mL-1) 
pre-incubated 10 mM GA (GA (10 mM)-BSA), 10 or 200 mM MGO (MGO (10 mM)-BSA and 
MGO (200 mM)-BSA, respectively) for 5 min at 21 ºC. Whilst low concentrations of GA-
modified BSA (0.4 (data not shown) and 1 mg protein mL-1) had no significant effects upon any 
of the proteasomal activities, high concentrations of this material (4 mg protein mL-1) 
significantly inhibited both the chymotrypsin- and caspase-like activities (Fig. 6A-D).  In 
contrast, this material stimulated trypsin-like activity (Fig. 6E).  BSA-modified with10 mM 
MGO had no effect upon any of the measured proteasomal activities at any of the protein levels 
examined.  With BSA modified with 200 mM MGO, an inhibition of caspase-like activity was 
observed at all the protein concentrations examined (Fig. 6C-D).  In addition, inhibition of both 
the chymotrypsin and trypsin activities was detected with the highest concentrations (4 mg 
protein mL-1) of this modified protein (Fig. 6B and F).     
 
Discussion  
This study has examined the effects of short-term exposure to glucose, reactive aldehydes 
and pre-glycated proteins on the activities of one of the major components of the intracellular 
protein removal systems, the proteasome.  One of the defining features of diabetes is 
hyperglycaemia, with elevation of blood glucose levels from 5 mM to up to ca. 30 mM in 
extreme cases [32].  This elevation is glucose is associated with elevations in the levels of 
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reactive aldehydes derived from glucose and other metabolic processes, and the generation of 
glycated / glycoxidised proteins [32].  Elevated levels of these materials have been detected in 
people with diabetes and correlate with the extent and duration of disease [33-37].  Thus 
increases in the level of glycated haemoglobin, a commonly used marker of hyperglycaemia, 
have been shown to both correlate with, and predict future cardiovascular disease [35-37].  The 
effects of these materials on proteasome function have been studied here in cell extracts from a 
macrophage-like cell line, as such cells play a key role in the development of atherosclerosis - the 
major macrovascular complication of diabetes, and the most important contributing factor to 
mortality and morbidity in people with diabetes [38].  Partially-purified cell extracts were used in 
these studies as modulation of the proteasomal system in intact cells by these agents is difficult to 
assess without accompanying perturbation of other aspects of cell metabolism.  In their role as 
scavenging cells of the immune system, macrophages are likely to be exposed to glycated 
proteins as well as elevated glucose and reactive aldehydes [6,39].  However the effects of 
glucose, reactive aldehydes and glycated proteins upon cellular metabolism and proteasomal 
function are not yet fully understood, though there is considerable current interest in this area, 
with previous studies having examined, for example, the rates of degradation of glycated / 
glycoxidized proteins in other cell types and tissues [3,22,40-42], and the effect of reactive 
aldehydes and glycated proteins on the other major proteolytic system of cells, the endo-
lysosomal system (e.g. [3,7,43]).  
The data reported here demonstrate that the effects of glucose, reactive aldehydes and 
glycated proteins on the three major activities of the proteasome are diverse and complex, with 
both stimulation and inhibition detected under different conditions.  The data obtained indicate 
that free reactive aldehydes induce more pronounced effects on proteasomal enzyme activities 
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than glucose itself under the same conditions.  This is consistent with previous data that have 
indicated that reactive aldehydes are considerably more reactive (up to 20,000-fold) than glucose 
itself [15,25], though these aldehydes are present at much lower levels (see below).  Glucose is 
the most abundant, but is also considered to be the least deleterious of the common sugars present 
in human [3].  In vivo studies have suggested that elevated levels of glucose alone are insufficient 
to accelerate diabetes-associated atherosclerosis [44].  The results of the current study are also 
consistent with previous studies that have reported that elevated levels of glucose did not inhibit 
some cytosolic (e.g. glyceraldehyde-3-phosphate dehydrogenase, GAPDH, and glutathione 
reductase) and lysosomal enzymes (e.g. the cysteine-dependent cathepsins, B and L), in vitro, 
whereas reactive aldehydes showed marked inhibitory effects [7,23].   
In contrast to these previous reports of enzyme inhibition induced by reactive aldehydes 
(see above), the major effect observed in the current study was a stimulation of proteasomal 
enzymatic activity.  A similar enhancement of nuclear proteasomal activity has been detected in 
intact cells treated with GO [45], though the exact mechanism by which this occurs has not been 
identified.  A number of treatments, such as incubation with basic polypeptides, SDS and fatty 
acids have previously been shown to activate the 20S proteasome by a mechanism that involves 
changes in protein conformation [20].  Thus alterations in the conformation of the β subunits 
have been proposed to enhance catalytic activity, and changes in the α ring may facilitate 
substrate entry to the catalytic core [20].  In the case of the 26S proteasome examined here, 
reactive aldehyde-induced alteration to either the lid or base of the 19S proteasome that delivers 
substrates to the proteolytic core may also play a role.  As the species used to assess enzymatic 
activity in the current study were small peptides, rather than large proteins, changes in the 
conformation of the β subunits may be the most likely cause of the observed stimulation of 
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activity, as the entry of these (unstructured / unfolded) peptides in to the protein core are less 
likely to be affected by steric factors, though this obviously requires further study.  It has also 
been reported that post-translational modifications of the proteasome complex (or its subunits) 
including phosphorylation and acetylation, can modulate proteasomal activities [19,46,47].  Thus 
phosphorylation of the α subunits appears to enhance activity of the proteasome in mammalian 
cells, possibly by inducing conformational changes that modulate substrate accessibility [46].  
Modification of specific Arg or Lys residues on proteasomal subunits by the reactive aldehydes 
under study (cf. data in Fig. 3) may induce similar conformation changes, and it is therefore of 
interest to note that enhanced levels of glycated (Nε-carboxymethyllysine containing) proteasome 
protein have been detected in aging cells [48].  In contrast, acetylation of the N-terminal Thr 
residue of the active β subunits and the α subunits results in inactivation of 20S proteasome 
[19,47].  A number of oxidants have also been shown to alter proteasome activity, with both 
inhibition [49,50] and activation reported [51].  Up-regulation of proteasome activity may be of 
considerable biological relevance in light of the key role that this complex plays in the 
degradation of inhibitory proteins, such as IκB, which prevents NF-κB activation and signalling 
[52], as has been reported in atherosclerotic plaques from people with diabetes [53].  
The data reported here are in contrast to a previous study that reported an inhibitory effect 
of GO on proteasomal enzyme activities in vitro [22].  There are however, a number of 
significant differences between these two studies, with this previous investigation showing that 
GO inhibited the 20S proteasome purified from human placenta after a 30 min incubation period 
[22]; this preparation lacks the regulatory subunits present on the 26S form, and hence effects of 
the reactive aldehydes on substrate accessibility and the control of this process, would not have 
been detectable in this earlier study.  The 20S form of the proteasome was not examined in the 
 19 
current study, as the majority of protein turnover in eukaryotic cells appears to occur via the 26S 
complex [21,54].  Furthermore, whilst the short incubation times employed in the current study 
may be sufficient to alter the conformational structure of the 26S complex in such a way as to 
allow greater substrate accessibility and thus enhanced activity, the longer incubation times, used 
by Bulteau and colleagues [22], may result in the accumulation of more severe damage to the 20S 
core and a suppression of enzyme activity. 
In contrast to the absence of effects induced by free glucose, significant changes in 
activity were detected with BSA pre-treated with glucose.  With low (pathologically-relevant) 
concentrations of glucose (10 mM, 17 h), and short incubation times with high glucose (200 mM 
glucose, 17 h), a small but significant stimulation of the trypsin-like activity was detected with 
the highest concentrations of glycated protein examined.  However with heavily glycated BSA (1 
M glucose, 8 weeks) marked inhibition of both the chymotrypsin- and caspase-like activities 
were observed and the stimulation of trypsin-like activity was reversed.  With the short 
incubation times (17 h) only low levels of early (reversible) glycated adducts would be expected 
to be formed with glucose (10 and 200 mM), as a chemical relaxation time of about 2.5 h has 
been reported for glucose and human serum albumin (HSA) in blood plasma to give the Schiff’s 
base under physiological conditions [55]. This low level of modification has been confirmed here 
(Fig. 3).  Subsequent rearrangement of this species to fructosamine or an Amadori product occurs 
over a much longer time-scale with equilibrium reached by ca. 38 h [55].  Thus it would appear 
that the formation of low levels of early (reversible) adducts on BSA do not significantly inhibit 
proteasomal enzymatic activities, whereas the advanced glycation products that are formed in 
high yield as a consequence of very high glucose concentrations and long term incubation (Fig. 
3), have marked inhibitory effects.  An absence of marked inhibitory effects with the combination 
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of BSA and short-term glucose incubation has also been reported for lysosomal cysteine-
dependent cathepsins [7].  The inhibition observed with high glucose/long term incubation are 
consistent with those of Stolzing and colleagues [41] for isolated 20S proteasomes where 
inhibition of the chymotrypsin-, caspase- and trypsin-like activities was observed on incubation 
with AGE-BSA (produced by incubation of BSA with 0.25 and 1 M glucose for 6 weeks) for 1 h.  
In both the current study and this previous work [41] the caspase-like activity appears to be the 
most markedly affected, and it is clear from the current data that this inhibition is rapid and can 
occur in < 5 min. 
Reactive aldehydes are known to be generated during glucose degradation (e.g. over a 3 
week period at pH 7.4 and 37 °C), and that the presence of proteins, such as HSA, enhances their 
rate of formation [55].  Elevated levels of these aldehydes have also been detected in human 
plasma from people with diabetes compared to healthy controls, though there is considerable 
variation in the reported values [56-58].  The high reactivity of these aldehydes [55] with 
nucleophilic sites present on proteins (primarily Arg, Lys, His and Cys side-chains and the N-
terminal amino group), limits the concentration of these materials in plasma, and these values 
represent steady state concentrations at the time of sampling, rather than the overall fluxes of 
modifying agent to which a protein may be exposed over its lifetime. Whether these plasma 
levels reflect those present within cells is also unclear, and no specific measurements have been 
reported for cells.  As many of the metabolic processes that generate reactive aldehydes are 
intracellular (e.g. decomposition of triose phosphates [13]) it is likely that cellular levels will be 
higher than those detected in plasma where the levels may reflect primarily glucose auto-
oxidation and efflux of the reactive aldehydes from cells.  Higher fluxes might also be expected 
at sites of inflammation (e.g. within the artery wall during the development of atherosclerosis) as 
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a result of the localisation of enzymes that can generate reactive aldehydes at such sites (e.g. 
myeloperoxidase which generates GO and MGO from the amino acids serine and threonine [14]).  
It is already established that other products of myeloperoxidase-mediated reactions accumulate 
on proteins to much higher levels in atherosclerotic lesions than are present in plasma / serum (up 
to 8-fold greater for apolipoprotein A-I, ca. 100-fold for apolipoprotein B-100 and ca. 115-fold 
for total protein [59,60]).  In addition it is well established that there is a marked accumulation of 
lipid oxidation products, another potential source of reactive aldehydes, in atherosclerotic lesions, 
with these levels massively exceeding those in plasma [61]. These data suggest that higher levels 
of reactive aldehydes are likely to be present in atherosclerotic lesion and surrounding tissue, than 
might be detected in plasma.  Thus measurements of steady-state levels of reactive aldehydes in 
plasma, may provide very limited information on the overall fluxes of reactive aldehydes to 
which proteins may be exposed within cells and tissues, and particularly at the sites of developing 
micro- and macrovascular complications in diabetes.  
In the light of the above discussion, it is possible that the inhibitory effects observed with 
highly glycated BSA on the chymotrypsin- and caspase-like activities of the proteasome may 
arise from reactions of reactive aldehydes formed from glucose over the extended incubation 
period, rather than from direct glucose reactions (cf. the elevated levels of CML and CEL 
detected on the BSA incubated with glucose for 8 weeks). This conclusion is consistent with the 
observed inhibitory effect of BSA pre-glycated with the aldehydes (as opposed to the stimulation 
detected with the free aldehydes themselves), with this inhibition being most evident with the 
caspase- and chymotrypsin-like activities.  Thus inhibition of both activities was detected with 4 
mg mL-1 of BSA pre-glycated with 10 mM GA (in contrast to a stimulation of trypsin-like 
activity).  In contrast, with the same concentrations of MGO, no significant changes in activity 
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were detected, though inhibition was again seen (with all three activities) with higher 
concentrations of MGO.  These data suggest that the species generated by GA, such as CML (cf. 
Fig. 3) have a greater inhibitory effect than those generated by MGO (CEL and MG-H1/2), 
though whether this is a manifestation of the nature of these products, or their relative yields is 
unclear.  These inhibitory effects of pre-glycated proteins mirror the suppressive effects of 
similar species on the activity of lysosomal cathepsins [7,62].  
Previous studies have shown that incubation of MGO with BSA at a molar ratio of 10:1 
results in a rapid increase in both irreversible and reversible binding of MGO to BSA and a rapid 
decrease in free MGO over 24 h [15]. The major sites of irreversible adduction under these 
conditions are Arg residues with this yielding imidazolones including MG-H1 and MG-H2a/b 
[15]. Incubation of GA with BSA at a molar ratio of 200:1, results in modification of Lys 
residues and generates C-2-imine cross-links and CML, with the maximum formation of these 
products detected after ca. 30 min [63]; these data are consistent with the results obtained in the 
current study (cf. Fig. 3), where the molar ratios of aldehyde:BSA were 8, 166 and 8 for the 10 
and 200 mM MGO, and 10 mM GA conditions respectively.  The AGE products formed on the 
BSA may be responsible for the observed inhibition of enzymatic activity, though it is also 
possible that this arises from loss of the parent amino acid side chains. Whether, and exactly 
which, AGE species is / are responsible for inhibition, cannot be discerned from the present data 
due to the difficulty in generating specific individual modifications, in isolation, on this protein.  
However it is clear from the data obtained that the extent of proteasomal enzyme alteration by 
glycated proteins varies with: (A) the total amount of glycated proteins that the proteasomal 
preparations are exposed to, (B) the nature of the glycating agent, (C) the extent of glycation at a 
fixed incubation time and protein concentration, and (D) the nature of proteasomal active site, 
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with the sensitivity to inhibition typically following the order caspase-like > chymotrypsin-like > 
trypsin-like. 
The mechanism of inhibition may be any of the following: (1) glycation may result in the 
formation of protein cross links and AGE that stabilize the BSA structure [18,22,64] resulting in 
a slower rate of degradation by 26S proteasome, and hence slower cleavage of the peptide used to 
assess enzyme activity as a result of competition for active sites [22]; (2) the glycated BSA may 
react, of form an adduct, with the nucleophilic oxygen of the Thr-1 residues in the β-type 
subunits [65] thereby inhibiting activity; (3) the AGE (or oxidation) products may modulate the 
structure or function of the α ring of catalytic core that facilitates the substrate entry [2,65] with 
this resulting in reduced access of the peptide substrate and hence a reduced rate of cleavage; or 
(4) the glycated protein may modulate (or block) the activity of 19S regulatory subunits, that 
control the access of substrates to the core [65].  Which of these mechanisms are operative in the 
current study cannot be determined from the current data, and further studies are required to 
elucidate this point.  
One imitation of the current investigation is the use of cell extracts that contain the 
proteasome, rather than highly purified preparations.  The former were employed due to 
difficulties in isolating sufficient active 26S complex from cells, without significant inactivation 
and / or loss of the 19S subunits that would compromise data analysis.  However the cruder cell 
extracts are likely to contain other non-proteasomal proteases, such as calpains and possibly 
lysosomal cathepsins [21].  Possible contributions of these non-proteasomal enzymes to the 
observed proteolytic activity was minimised by quantifying activity at pH 7.4, where most 
lysosomal enzymes show little activity [21], and by including parallel epoxomicin-treated 
samples.  Subtraction of residual activity obtained in the presence of this specific proteasomal 
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inhibitor [66], from the total activity, provided data that has been ascribed to the proteasome [21].  
However, in some experiments this resulted in an apparent “negative” activity which is consistent 
with the glucose / free aldehyde or glycated proteins also inhibiting non-proteasomal activity in 
the samples, resulting in activities lower than those of the epoxomicin controls.  Potential 
circumvention of this effect by either pre- or post-treating the incubations with epoxomicin was 
considered but not attempted as this would result in different overall incubation periods and 
potentially misleading data.  Blockade of other contributing proteolytic activities by use of 
inhibitors was not attempted due to the diverse and unknown nature of all of these activities and 
the non-availability of specific inhibitors.  
In conclusion, glycated proteins generated by either reactive aldehydes or long-term 
exposure to high glucose concentrations has been shown to inhibit the chymotrypsin-, caspase- 
and to a lesser extent the trypsin-like activities of proteasomal fractions from J774A.1 cells.  This 
suppression of proteasome activity by glycated proteins, in conjunction with the previously 
reported inhibition of lysosomal cathepsin enzymes by the same species [7] may contribute to the 
intracellular accumulation of glycated and otherwise damaged proteins in people with diabetes.  
A decreased rate of intracellular catabolism of these glycated proteins is likely to result in an 
higher concentration (accumulation) and increased residence time of these materials within cells 
resulting in an enhanced level of further secondary reactions and advanced glycation products.  A 
longer half-life for these modified proteins within cells would also be expected to increase the 
likelihood of protein cross-linking and aggregation, with deleterious consequences on cellular 
function, and result in a further inhibition of protein catabolism.  Thus a vicious, self-sustaining, 
cycle of ever-increasing cellular dysfunction may result in cells exposed to these agents and 
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Fig. 1.  Effect of free glucose on proteasomal enzyme activities in J774A.1 cell extracts.  Cell 
extracts were incubated with glucose (0, 5 or 20 mM) for 5 min at 21 ºC.  Then the 
chymotrypsin-, caspase- or trypsin-like activities were assessed and analysed as described in the 
Materials and Methods.  White, grey and black bars represent proteasomal activity of cell extracts 
incubated with 0, 5 and 20 mM glucose, respectively.  * P < 0.05 compared to 0 mM glucose 
condition using one way ANOVA and Newman-Keuls multiple comparison test.  Data are mean 
± SEM of three or more experiments. 
 
Fig. 2.  Free reactive aldehydes enhance proteasomal enzyme activities.  Cell extracts were 
incubated with GA and GO (0, 1, 10 and 20 mM), and MGO (0, 0.25, 0.5, 1, 10 and 20 mM) for 
5 min at 21 ºC.  The (A) chymotrypsin -, (B) caspase -, and (C) trypsin-like activities were 
measured as described in the Materials and Methods.  White bars represent control, dotted bars 
show 0.25 mM (MGO and trypsin-like activity only), cross hatched bars represent 0.5 mM 
(MGO and trypsin-like activity only), grey bars show 1 mM, black bars represent 10 mM and 
hatched bars represent 20 mM treatments.  * P < 0.05 or # P < 0.05 for results compared to 
control or to other treatments, respectively, using one way ANOVA and Newman-Keuls multiple 
comparison test.  Data are mean ± SEM of three or more experiments. 
 
Fig. 3.  Characterization of AGE formation and parent amino acid loss on glycated BSA samples. 
Control and glycated BSA samples, prepared as indicated in the text, were analysed by HPLC 
after fluorescent tagging. Concentrations were determined by comparison with authentic 
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standards of AGE or parent amino acids derivatized under identical conditions. Data for AGE are 
expressed as mmoles product relative to moles of parent Gly, as amino acid not expected to be 
modified by glycation; this comparative measure accounts for any protein loss during processing.  
Values for control BSA samples taken through identical protocols have been subtracted from the 
treatment data; in all cases these control data were typically < 0.2 mmol AGE/mole Gly. Data for 
parent amino acid are expressed as a % of the levels detected in control BSA. Absolute levels of 
the amino acids quantified accorded with the expected amino acid composition from protein 
databases. Data are mean + SD for triplicate determinations from separate experiments. * P < 
0.05 relative to the corresponding BSA control for each condition, using 2-tailed unpaired t tests.  
 
Fig. 4. Effect of native incubated BSA on proteasomal enzyme activities of J774A.1 cell extracts.  
White, black and grey columns represent 5 min incubation of cell extracts at 21 ºC with 0, 1 and 
4 mg/ml of control BSA that was incubated for 17 h or 8 weeks.  Proteasomal enzyme activities 
of J774A.1 cell extracts after treatment were determined using (A) chymotryptic, (B) caspase or 
(C) tryptic substrate and measurement of specific activities as described in the Materials and 
Methods.  * P < 0.05, using one-way ANOVA and Newman-Keuls multiple comparison test to 
relevant control.  Each column represents mean ± SEM of 3 or more experiments. 
 
Fig. 5.  Effect of BSA, pre-glycated with glucose, on proteasomal enzyme activity of J774A.1 
cell extracts.  BSA was pre-glycated with 10 or 200 mM glucose for 17 h or 1 M glucose for 8 
weeks as described in Materials and Methods.  White and grey bars represent control-BSA and 
BSA glycated with glucose, respectively.  Cell extracts were incubated with 1 mg/ml (A, C and 
E) or 4 mg/ml (B, D and F) of glycated-BSA or control BSA for 5 min at 21 ºC, then the specific 
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proteasome substrate was added and the activities were measured as described in text.  * P < 
0.05, using two-tailed paired-t tests.  Each column represents mean ± SEM of 3 experiments. 
 
Fig. 6.  Effects of BSA pre-glycated with reactive aldehydes on proteasomal enzyme activities of 
J774A.1 cell extracts.  Cell extracts were incubated with 1 mg/ml (A, C and E) or 4 mg/ml (B, D 
and F) of control BSA, or BSA modified using 10 mM GA, 10 mM MGO or 200 mM MGO, for 
5 min at 21 °C.  Chymotrypsin-, caspase- or trypsin-like activity was measured as described in 
Materials and Methods.  White and grey bars represent control-BSA and modified-BSA by 
reactive aldehydes, respectively.  * P < 0.05, using a two-tailed paired-t test relative to the 
corresponding control BSA.  Each column represents mean ± SEM of three experiments.   
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